<div id="readability-page-1"><div><p>Insiders who bought <strong>Context Therapeutics Inc.</strong> (NASDAQ:CNTX) in the last 12 months may probably not pay attention to the stock's recent 10% drop.  After taking the recent loss into consideration, the US$107.1k worth of stock they bought is now worth US$344.0k, indicating that their investment yielded a positive return.</p><p> While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing,  logic dictates you should pay some attention to whether insiders are buying or selling shares. </p> <p>This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.</p><h2> Context Therapeutics Insider Transactions Over The Last Year </h2> <p> Over the last year, we can see that the biggest insider purchase was by Co-Founder Martin Lehr for US$70k worth of shares, at about US$0.70 per share.   Even though the purchase was made at a significantly lower price than the recent price (US$2.15), we still think insider buying is a positive.  Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.   </p> <p> In the last twelve months Context Therapeutics insiders were buying shares, but not selling.    The chart below shows insider transactions (by companies and individuals) over the last year.  If you want to know exactly who sold, for how much, and when, simply click on the graph below! </p><p><span> View our latest analysis for Context Therapeutics </span></p><p> Context Therapeutics is not the only stock insiders are buying. So take a peek at this <strong>free</strong> list of under-the-radar companies with insider buying. </p> <h2> Does Context Therapeutics Boast High Insider Ownership? </h2><p> Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders.  We usually like to see fairly high levels of insider ownership.   Based on our data, Context Therapeutics insiders have about 1.4% of the stock, worth approximately US$2.7m.  We prefer to see high levels of insider ownership.  </p><h2> So What Does This Data Suggest About Context Therapeutics Insiders? </h2><p> The fact that there have been no Context Therapeutics insider transactions recently certainly doesn't bother us.    But insiders have shown more of an appetite for the stock, over the last year.   While we have no worries about the insider transactions, we'd be more comfortable if they owned more Context Therapeutics stock.      So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company.    When we did our research, we found <strong>3 warning signs for Context Therapeutics</strong> (1 is significant!) that we believe deserve your full attention.  </p><p> Of course <strong>Context Therapeutics may not be the best stock to buy</strong>. So you may wish to see this <strong>free</strong> collection of high quality companies. </p><p><em>For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.</em></p></div></div>

CNTX

LABU

SBIO

ARKG

IBBQ

<p>Context Therapeutics Inc. (NASDAQ:CNTX) insiders have seen their investments yield positive returns despite a recent 10% stock drop. Over the past year, insiders bought shares worth US$107.1k, now valued at US$344.0k. The largest purchase was by Co-Founder Martin Lehr for US$70k at US$0.70 per share. Insiders currently hold about 1.4% of the stock, valued at US$2.7m, indicating a preference for higher insider ownership. Recent insider buying suggests confidence, but there are three significant warning signs to consider.</p>

Simplywall

Context Therapeutics

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Context Therapeutics Decline Means Insider Profits Down To US$237k